The Aquatic Animal Drug Approval Partnership (AADAP) recently hosted the 31st Aquaculture Drug Approval Coordination Workshop, held jointly with the Western Fish Disease Workshop and the American Fisheries Society Fish Health Section Annual Meeting. Each member of the AADAP team presented on various topics such as INAD updates and unmet drug needs, showcasing their collective expertise and insights.
It was a valuable opportunity to connect with fish health professionals from across the country and Canada. The team greatly appreciated hearing the presentations and engaging in meaningful discussions. The collaborative atmosphere created an enriching experience filled with learning and networking.
The AADAP team looks forward to next year’s workshop, scheduled for July 21–23, and to continuing to strengthen connections within the fish health community. To stay updated, check the FWS website for news.
Ovaprim Now Indexed for Use in All Finfish Broodstock
Ovaprim has now been indexed for use in all finfish broodstock. This means the product can be used on broodstock as long as the fish will never be harvested for consumption. The label expansion was facilitated by the Expert Panel Report authored by Dr. Roy Yanong (University of Florida), Dr. Matt DiMaggio (University of Florida), and Dr. Shane Ramee (AADAP). This is the first indexed spawning hormone available for use in all finfish broodstock, but hopefully not the last.
Current and former AADAP researchers have been actively serving on a variety of indexing expert panels with the goal of expanding the legal availability of safe and effective products for use in non-food species and life stages of fish. This alternative pathway to legal use offers a less burdensome and more cost-effective option for drug sponsors to bring products to market and expand the medicine chest for a variety of non-food aquaculture applications.
AADAP extends thanks to Ovaprim’s sponsor, Syndel USA, for its continued dedication to providing the aquaculture community with safe, effective, and legal products to support all aspects of production.
AADAP Research Team Travels to Michigan for Pivotal Efficacy Study
In June, the AADAP Research Team traveled to Michigan to complete a pivotal efficacy study evaluating the use of Chloramine-T to control mortality caused by external bacterial coldwater disease (Flavobacterium psychrophilum) in juvenile spring steelhead trout (Oncorhynchus mykiss). Bacterial coldwater disease affects a variety of cultured and wild coldwater species, with hatchery-reared juvenile salmonids particularly vulnerable. The disease is most prevalent at water temperatures of 16°C and below and becomes increasingly severe below 10°C.
This pivotal study was a collaborative effort between AADAP, the Michigan Department of Natural Resources, and Michigan State University. The work would not have been possible without the assistance of these partners. The study results will be used in efforts to expand the existing approved label to include the use of Chloramine-T for treating salmonids with external bacterial coldwater disease.